Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014

American Journal of Public Health

Volumn 108, Issue 1, 2018, Pages 112-119

  Flagg, Elaine W ^a   Torrone, Elizabeth A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; INCIDENCE; INSURANCE; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; SEX RATIO; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 85037865946     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2017.304119     Document Type: Article

References (40)

1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-814.
2. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
3. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630-632.
4. Centers for Disease Control and Prevention. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304.
5. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708.
6. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
7. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620-624.
8. Centers for Disease Control and Prevention. Use of a 2-dose scheduleof human papillomavirus vaccination-updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405-1408.
9. Bruni L, Diaz M, Barrionuevo-Rosas L. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-e463.
10. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40):1100-1103.
11. Centers for Disease Control and Prevention. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784-792.
12. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671-677.
13. Centers for Disease Control and Prevention. National Health Interview Survey: 2010 data release. Available at: https://www.cdc.gov/nchs/nhis/nhis-2010-data-release. htm. Accessed March 15, 2017.
14. Centers for Disease Control and Prevention. Noninfluenza vaccination coverage among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2013;62(4):66-72.
15. Centers for Disease Control and Prevention. Surveillance of vaccination coverage among adult populations-United States, 2014. MMWR Surveill Summ. 2016;65(1):1-36.
16. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
17. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
18. Castle PE, Zhao FH. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis. 2011;204(3):335-337.
19. [Erratum in: J Infect Dis. 2011;204(7):1149]
20. Drolet M, Bénard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15(5):565-580.
21. Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine. 2011;29(5):878-885.
22. Egelkrout EM, Galloway DA. The biology of genital human papillomaviruses. In: Holmes KK, Sparling PF, StammWE, etal., eds Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw Hill Medical; 2008:463-487.
23. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738.
24. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103(8):1428-1435.
25. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(suppl 1):S97-S106.
26. Park IU, Introcoso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015;61(suppl 8):S849-S855.
27. Flagg EW, Torrone EA, Weinstock H. Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014. Am J Public Health. 2016;106(12):2211-2218.
28. National Cancer Institute. PC end points for rate sessions. Available at: https://seer.cancer.gov/seerstat/508-WebHelp/PC-End-Points-for-Rate-Sessions. htm. Accessed March 15, 2017.
29. National Cancer Institute. Joinpoint. Available at: https://surveillance.cancer.gov/help/joinpoint. Accessed March 15, 2017.
30. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226.
31. Ford K, Sohn W, Lepkowsk J. American adolescents: sexual mixing patterns, bridge partners, and concurrency. Sex Transm Dis. 2002;29(1):13-19.
32. Aral SO, Hughes JP, Stoner B, et al. Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health. 1999;89(6):825-833.
33. Korostil IA, Ali H, Guy RJ, Donovan B, Law MG, Regan DG. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis. 2013;40(11):833-835.
34. Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 2014;9(9):e105967.
35. Chow E P F, Read T R H, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214-219.
36. Markowitz LE, Liu G, Hariri S, Stenau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.
37. Gargano JW, Unger ER, Liu G, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis. 2017;215(7):1070-1079.
38. Centers for Disease Control and Prevention. Cancer screening test use-United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(17):464-468.
39. Baseman JG, Kautsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(suppl 1):S16-S24.
40. Anic GM, Lee JH, Stockwell H, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis. 2011;204(12):1886-1892.